New combo therapy shows promise for tough bile duct cancer
NCT ID NCT04834674
First seen Apr 10, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This study tested a three-drug combination for people with advanced bile duct cancer that worsened after standard chemotherapy. The treatment included chemo beads placed directly into the liver tumor, a targeted therapy pill (apatinib), and an immunotherapy drug (PD-1 antibody). The goal was to see if this combination could shrink tumors and slow cancer growth. The study enrolled 20 adults aged 18 to 80 with confirmed bile duct cancer that had spread or could not be surgically removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.